VivoSeq
Infectious Disease

Avian Influenza

12

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Avian Influenza is an emerging landscape with 12 programs across 4 companies. The most active players are Emergent BioSolutions, Inovio Pharmaceuticals, Novartis. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Emergent BioSolutions logo

Emergent BioSolutions

2 programs

Phase 1Inovio Pharmaceuticals logo

Inovio Pharmaceuticals

1 program

Phase 1Novartis logo

Novartis

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Vaccine

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSSmall molecule120%

Vaccine leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 15 pipeline programs.

Analysis

Trial Status

9

clinical trials

Completed8 · 89%
Active, not recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
Active, not recruiting·CCanadian Immunization Research Network·Phase 4·NCT07275060·312 enrolled
Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03682120·372 enrolled
High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00298233·326 enrolled
Safety Study of an Oral Vaccine to Prevent Avian Influenza
Completed·VVaxart·Phase 1·NCT01335347·54 enrolled
Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus
Completed·—·N/A·NCT01044095·26 enrolled
Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults
Completed·Inovio Pharmaceuticals logoInovio Pharmaceuticals·Phase 1·NCT01142362·32 enrolled
A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults
Completed·VVaxine Pty Ltd·Phase 1·NCT02335164·270 enrolled
Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00922259·25 enrolled
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
Completed·Emergent BioSolutions logoEmergent BioSolutions·Phase 1·NCT01006798·166 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)